Simvastatin blunts endotoxin-induced tissue factor in vivo

Area of Science:

• Pharmacology
• Immunology
• Cardiovascular Medicine

Background:

• Statins possess anti-inflammatory properties beyond lipid lowering.
• In vitro studies suggest statins inhibit lipopolysaccharide (LPS)-induced monocyte tissue factor (TF) expression.
• This study investigates statin effects on inflammatory and procoagulant responses in experimental endotoxemia.

Purpose of the Study:

• To evaluate the in vivo effects of simvastatin on inflammatory and procoagulant responses to LPS.
• To assess simvastatin's impact on monocyte TF expression and related inflammatory markers.
• To determine if simvastatin influences platelet activation during endotoxemia.

Main Methods:

• A double-blind, placebo-controlled study involving 20 healthy males randomized to simvastatin or placebo for 4 days.
• Intravenous LPS administration followed by measurements of plasma hsCRP, MCP-1, sCD40L, sCD40, and F1.2.
• Monocyte TF expression and monocyte-platelet aggregates assessed via whole-blood flow cytometry.

Main Results:

• Simvastatin significantly suppressed LPS-induced increases in hsCRP and MCP-1.
• Statin treatment blunted the rise in monocyte TF expression following LPS challenge.
• Simvastatin significantly reduced endotoxin-induced formation of prothrombin fragment F1.2.
• LPS infusion did not alter monocyte-platelet aggregate formation or plasma sCD40/sCD40L levels.

Conclusions:

• Simvastatin effectively suppresses the inflammatory response to endotoxin in vivo.
• Simvastatin attenuates monocyte tissue factor expression during experimental endotoxemia.
• Statin administration in this model did not affect platelet activation.